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Abstract
Background: Giant cell tumor (GCT) is usually a benign but locally aggressive primary bone
neoplasm in which monocytic macrophage/osteoclast precursor cells and multinucleated
osteoclast-like giant cells infiltrate the tumor. The etiology of GCT is unknown, however the tumor
cells of GCT have been reported to produce chemoattractants that can attract osteoclasts and
osteoclast precursors. Rarely, GCT can originate at extraosseous sites. More rarely, GCT may
exhibit a much more aggressive phenotype. The role of chemotherapy in metastatic GCT is not
well defined.
Case presentation: We report a case of an aggressive GCT of the uterus with rapidly growing
lung metastases, and its response to chemotherapy with pegylated-liposomal doxorubicin,
ifosfamide, and bevacizumab, along with a review of the literature.
Conclusion:  Aggressive metastasizing GCT may arise in the uterus, and may respond to
combination chemotherapy.
Background
Giant cell tumor (GCT) of bone, also known as osteoclas-
toma, is a primary osteolytic bone neoplasm in which
monocytic macrophage/osteoclast precursor cells and
multinucleated osteoclast-like giant cells infiltrate the
tumor [1-3]. Walker first demonstrated that osteoclasts
are derived from monocytic osteoclast precursors in blood
[4,5]. The origin of GCT is unknown, but the tumor cells
of GCT have been reported to produce chemoattractants
that can attract osteoclasts and their precursors [3,6].
GCT is usually benign but locally aggressive, and most
commonly occurs in the epiphysis of long bones. Rarely,
GCT can originate at extraosseous sites. Metastases from
GCT of bone are unusual, and often behave in an indolent
manner that can be managed by surgery [7]. More rarely,
GCT may exhibit a much more aggressive phenotype. The
role of chemotherapy in metastatic GCT is not well
defined. We report a case of an aggressive GCT of the
uterus with rapidly growing lung metastases, and its
response to chemotherapy with pegylated-liposomal dox-
orubicin, ifosfamide, and bevacizumab, along with a
review of the literature.
Case presentation
A 55 year old woman developed anorexia, vaginal bleed-
ing, and a non-productive cough over one month. Her last
menstrual period was 11 months earlier, and she had
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noted some vaginal spotting for 5 months. CT scans
revealed a large uterine mass and multiple lung nodules.
An endometrial curetting showed small fragments of
tumor consisting of two components; aggregates of atypi-
cal plump mononuclear cells with hyperchromatic, pleo-
morphic nuclei were interspersed with numerous large
multinucleated osteoclast-type giant cells, some of which
had more than 30 benign-appearing nuclei (Figure 1,
Top). Up to ten mitoses power high-power field were
observed in the mononuclear cells. Immunoperoxidase
stain for the histiocytic marker CD68 was positive in a
subpopulation of mononuclear cells and in the osteo-
clast-type giant cells. These cells were negative for the epi-
thelial marker cytokeratin (AE1/AE3) which highlighted
scattered benign endometrial glands. A fine needle aspi-
rate of the lung showed sheets of atypical mononuclear
plump cells and numerous scattered benign-appearing
osteoclast-type giant cells (Figure 1, Bottom). Some
mononuclear cells were positive for the endometrial stro-
mal marker CD10; all mononuclear and multinucleated
cells were positive for the mesenchymal cell marker
vimentin; CD117 (c-kit) was weakly positive in multinu-
cleated cells. All cells were negative for estrogen receptors,
cytokeratins (7, 20, AE1/AE3), muscle specific actin and
mucin.
On presenting to our clinic, her history was remarkable
for anorexia, uterine bleeding, dyspnea on exertion, a
non-productive cough, and a 10 pound weight loss during
the previous month. Her past history was notable for
treated hypertension and hypothyroidism, an episode of
gout, and monoclonal gammopathy of undetermined sig-
nificance. Her medications were lisinopril, L-thyroxine,
and a multivitamin. Her physical examination was nota-
ble for scattered crackles and occasional wheezes, and
mild lower abdominal tenderness and fullness. A repeat
CT scan revealed prominent tumor progression during the
preceeding month, with a 11.6 cm uterine mass and lung
nodules, some >4 cm in diameter (Figure 2). Hemoglobin
was 8.5 g/dl, AST, alkaline phosphatase, bilirubin, creati-
nine, and electrolytes were normal. Treatment was begun
with pegylated-liposomal doxorubicin (45 mg/m2, day
1), ifosfamide (9 g/m2 total dose given by continuous
infusion over 6 days, days 1–6) with mesna uroprotection
[8], and bevacizumab 5 mg/kg every 2 weeks, with pegfil-
grastim 6 mg given subcutaneously on day 7, with cycles
repeated every 28 days. After the first cycle of chemother-
apy, repeat CT imaging revealed a tumor response in the
lung nodules (Figure 3), although her symptoms were
unchanged. At the start of cycle 3 her cough, vaginal
bleeding, and dyspnea on exertion had noticeably
improved. The dose of pegylated-liposomal doxorubicin
was decreased by 10% for the third and subsequent cycles
due to mucositis and skin rash. A CT scan before cycle 4
showed continued tumor regression. Blood pressure
remained controlled and no proteinuria was noted. After
7 cycles the tumor had stabilized by CT imaging (Figure
4). The lung nodules had largely disappeared, but the
uterine mass remained at about 8.5 cm. She was given
cycle 8 without bevacizumab in anticipation of hysterec-
tomy. Repeat CT imaging showed stable disease, and she
underwent a total abdominal hysterectomy with bilateral
salpingo-oophorectomy 8 weeks after cycle 8.
The uterus contained a poorly demarcated tumor that
measured 4.8 × 4.0 × 3.5 cm arising in the left lateral wall
(Figure 5, Top). Multiple leiomyomata ranging from 0.3
to 2.2 cm were also identified. Sections from the tumor
(Figure 5, Bottom) showed atypical mononucleated
Top, endometrial curetting showed aggregates of plump  mononuclear cells with numerous large multinucleated oste- oclast-type giant cells Figure 1
Top, endometrial curetting showed aggregates of plump 
mononuclear cells with numerous large multinucleated oste-
oclast-type giant cells. Benign endometrial glands are seen at 
right center and right upper corner. Bottom, Fine needle 
aspirate of the lung showed sheets of mononuclear plump 
cells and numerous scattered osteoclast-type giant cells. See 
the text for complete pathologic description.BMC Cancer 2007, 7:46 http://www.biomedcentral.com/1471-2407/7/46
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plump to spindle shaped tumor cells diffusely infiltrating
the myometrium and within dilated blood vessels. Tumor
cells accounted for approximately 30 % of the cells. Vas-
cular invasion was observed. Occasional multinucleated
giant cells of osteoclastic-type were also recognized; how-
ever, these were rare and tended to form small aggregates.
Extensive areas of necrosis showed dystrophic calcifica-
tion. Large numbers of histiocytes with foamy cytoplasm
and hemosiderin granules were observed throughout the
tumor; these cells accounted for approximately 70% of
the cellular population. A subpopulation of mononuclear
cells was positive for CD10; osteoclastic cells were non-
reactive. Some of the mononuclear plump and spindle
cells were weakly positive for actin; they were negative for
desmin and smooth muscle myosin. CD117 was weakly
positive in the osteoclastic cells. The cell division marker
Ki67 was positive in tumor cells and negative in histio-
cytes and osteoclasts; Stains for common leukocyte anti-
gen (CD45) and for the histiocytic marker CD68 were
positive in histiocytes and osteoclasts, but were negative
in tumor cells. Stains for lysozyme were weakly positive in
histiocytes and osteoclasts but were negative in tumor
cells. Stains for cytokeratin (AE1/AE3), estrogen receptors,
and progesterone receptors were negative. Pelvic washings
were negative; the cervix, parametria, tubes, and ovaries
were free of tumor.
Two months after the hysterectomy, progression of the
lung nodules was noted on CT imaging and therapy with
pegylated-liposomal doxorubicin and bevacizumab was
begun, but progression was noted after 2 months. Gemcit-
abine (675 mg/m2 intravenously over 90 min given days
1 and 14 with pegfilgrastim days 2 and 15 due to neutro-
penia on day 8 of the first cycle, with cycles repeated every
28 days) [9,10] with bevacizumab was begun, but pro-
gression was noted after two months. Therapy was then
CT scan at start of chemotherapy cycle #2 Figure 3
CT scan at start of chemotherapy cycle #2.
CT scan at start of chemotherapy Figure 2
CT scan at start of chemotherapy.BMC Cancer 2007, 7:46 http://www.biomedcentral.com/1471-2407/7/46
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begun with ifosfamide and etoposide [8] and bevacizu-
mab, and a partial response was observed after two
months, with stabilization at 4 months. The patient
received a total of 6 cycles of ifosfamide, etoposide, beva-
cizumab, although bevacizumab was held on day 14 of
cycle 6 due to proteinuria. Two months later significant
progression was noted. She received 1 cycle of dacar-
bazine, mitomycin c, and cisplatinum, with a very good
response, but prominent toxicity including myelosup-
pression and fatigue. Two months later tumor progression
was noted.
Conclusion
The current report describes an unusual case of aggressive
GCT of the uterus and its response to chemotherapy with
pegylated-liposomal doxorubicin, ifosfamide, and bevaci-
zumab. The role of chemotherapy in GCT is not well
defined. Pegylated-liposomal doxorubicin and ifosfamide
are active in soft tissue and bone sarcomas [8,11-15]. Ang-
iogenic growth factor expression, including VEGF, has
been previously reported in a variety of sarcomas and in
GCT of bone [16-23], providing a rationale for the poten-
tial role of therapy directed against the VEGF signaling
pathway, such as bevacizumab, in sarcomas, including
GCT. In addition, VEGF is capable of inducing osteoclas-
togenesis in osteopetrotic mice (op/op) [24]. The current
case responded well to therapy with pegylated-liposomal
doxorubicin, ifosfamide, and bevacizumab. It is of inter-
est that in the first two specimens obtained before treat-
ment (endometrial curetting and lung aspirate) there were
large numbers of giant cells and these were evenly distrib-
uted. In contrast, the hysterectomy specimen after chemo-
therapy, showed only rare osteoclast-type giant cells, and
Top, the hysterectomy specimen contained residual poorly  demarcated tumor (left) and multiple leiomyomata (right) Figure 5
Top, the hysterectomy specimen contained residual poorly 
demarcated tumor (left) and multiple leiomyomata (right). 
Bottom, sections from the uterine tumor showed residual 
mononucleated plump to spindle shaped tumor cells (left 
upper corner) and inflammatory cells, including foamy mac-
rophages, osteoclast-type giant cells, and histiocytes (lower 
right). See the text for complete pathologic description.
CT scan at start of chemotherapy cycle #8 Figure 4
CT scan at start of chemotherapy cycle #8.BMC Cancer 2007, 7:46 http://www.biomedcentral.com/1471-2407/7/46
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there was extensive replacement of tumor cells by necrosis
and reactive histiocytes.
Usually GCT is a primary osteolytic bone neoplasm in
which monocytic macrophage/osteoclast precursor cells
and multinucleated osteoclast-like giant cells infiltrate the
tumor [1-3,6]. These multinucleated giant cells have bio-
chemical and functional characteristics of osteoclasts
(reviewed in [18]). While usually benign, GCT is locally
aggressive and most commonly occurs in the epiphysis of
long bones. GCT of soft parts are very rare, but have been
described [25,26], as have GCT of the thyroid [27] and
pancreas [28,29].
Pulmonary metastases of GCT of bone usually grow
slowly, and are often treated by surgery, though in some
cases chemotherapy with various agents or radiation ther-
apy have been used [30-39]. Two cases of rapidly progres-
sive metastatic GCT of bone have been reported that were
treated with chemotherapy with a transient response
[40,41]. Several reports have suggested the potential util-
ity of interferon alpha in GCT of bone [30,42-44].
Walker observed that osteoclasts are derived from mono-
cytic progenitors found in the blood [4,5], providing the
first demonstration of the existence of stem cells in blood
for non-hematopoietic tissue. The etiology of GCT is
unknown, however the tumor cells of GCT have been
reported to produce chemoattractants that can recruit
osteoclasts and osteoclast precursors [3,6].
Many reactive conditions and benign and malignant
tumors contain osteoclast-type giant cells. An important
difference between many of these entities and the "true"
giant cell tumor is that the spatial relationship between
the giant cells and the tumor cells is different. In giant cell
tumor, the osteoclast-type giant cells are distributed regu-
larly and uniformly throughout the tumor; in other enti-
ties, the giant cells tend to be clustered, frequently in areas
of hemorrhage, that alternate with areas completely
devoid of giant cells. This difference in distribution prob-
ably reflects differences in pathogenesis. It has been sug-
gested that in the various entities with unevenly
distributed giant cells, the latter are probably the result of
cytokines produced that attract osteoclast precursors. In
giant cell tumor, the even distribution may reflect interac-
tion/co-dependence as in a paracrine loop between the
tumor stromal cells and the reactive, osteoclast type giant
cells.
We found reports of 9 other cases of GCT of the uterus
[45-51]. Three patients in whom follow up was available
died of their tumors. Four of the cases were thought to
also have smooth muscle differentiation. Absence of
desmin and myosin and only focal and weak reactivity for
actin argue against true smooth muscle differentiation in
our case.
The tumor cells of GCT of bone have been reported to pro-
duce chemoattractants, including both TGF beta1 and
monocyte chemoattractant protein 1 (MCP-1), that can
attract osteoclasts and TRAP-positive monocytic osteo-
clast precursors. Other growth factors indicative of an
osteoclastogenic environment of potential importance in
GCT, including RANKL, have been identified in GCT
[6,18,52-54]. RANKL (OPGL) binds specific hematopoi-
etic progenitor cells and induces osteoclast differentia-
tion. RANKL also activates osteoclasts, and administration
of RANKL to mice results in hypercalcemia [55]. RANKL is
necessary and sufficient for osteoclastogenesis [52].
RANKL mRNA expression was recently reported to be
over-expressed in the stromal-like tumor cells of GCT,
while its receptor, RANK, was expressed only in the mac-
rophage-like mononuclear cells and multinucleated giant
cells [6,52-54]. The potential role for tumor cell-osteoclast
interaction/co-dependence, as in a paracrine loop
between the stromal tumor cells and the osteoclast-like
cells, in GCT is unknown. In this regard, it is of interest
that the marked decrease in the population of viable
tumor cells in the hysterectomy specimen after chemo-
therapy was associated with a marked reduction in the
number of osteoclast-type giant cells and with loss of their
spatial relationship. Thus, it is intriguing to speculate that
new agents that inhibit osteoclastogenesis via the RANK/
RANKL pathway, such as denosumab, could be useful in
the treatment of GCT. Recent studies also suggest that
bisphosphonates may induce apoptosis in both osteo-
clast-like giant cells and stromal tumor cells in vivo and in
vitro in GCT [56,57], possibly by interfering with an auto-
crine and/or paracrine loop in the tumor between stromal
tumor cells and osteoclast-like giant cells.
Aggressive metastasizing GCT may arise in the uterus, and
may respond to combination chemotherapy. The addi-
tion of bevacizumab is logical, though its contribution to
the effect observed in this case is unclear.
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